Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth Marek

Showing results (71-80 of 144) with videos related to

Pageof 15
Sort By:
Journal of Parkinson'S Disease|August 28, 2019
Predicting Progression in Parkinson's Disease Using Baseline and 1-Year Change MeasuresLana M Chahine, Andrew Siderowf, Janel Barnes, et al.
Clinical and Translational Science|July 28, 2017
Dopamine Transporter Neuroimaging as an Enrichment Biomarker in Early Parkinson's Disease Clinical Trials: A Disease Progression Modeling AnalysisDaniela J Conrado, Timothy Nicholas, Kuenhi Tsai, et al.
The Lancet. Neurology|July 21, 2023
Safety and efficacy of venglustat in GBA1-associated Parkinson's disease: an international, multicentre, double-blind, randomised, placebo-controlled, phase 2 trialNir Giladi, Roy N Alcalay, Gary Cutter, et al.
Clinical and Translational Science|February 2, 2019
Molecular Neuroimaging of the Dopamine Transporter as a Patient Enrichment Biomarker for Clinical Trials for Early Parkinson's DiseaseKlaus Romero, Daniela Conrado, Jackson Burton, et al.
Annals of Neurology|April 27, 2026
Insights Gained From the PPMI Brain Donation ProgramTatiana Foroud, Laura E A Heathers, Syed Bukhari, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|August 20, 2009
A longitudinal program for biomarker development in Parkinson's disease: a feasibility studyBernard Ravina, Caroline Tanner, Diane Dieuliis, et al.
Annals of Neurology|May 6, 2026
Biologic Frameworks for Synucleinopathies: Contributions of the Parkinson's Progression Markers InitiativeLana M Chahine, Roy N Alcalay, Ethan G Brown, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|April 4, 2017
The prodromal phase of leucine-rich repeat kinase 2-associated Parkinson disease: Clinical and imaging StudiesClaustre Pont-Sunyer, Eduardo Tolosa, Chelsea Caspell-Garcia, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 13, 2019
Tau PET imaging with <sup>18</sup>F-PI-2620 in Patients with Alzheimer Disease and Healthy Controls: A First-in-Humans StudyAndre Mueller, Santiago Bullich, Olivier Barret, et al.
NPJ Parkinson'S Disease|October 22, 2022
Longitudinal clinical and biomarker characteristics of non-manifesting LRRK2 G2019S carriers in the PPMI cohortTanya Simuni, Kalpana Merchant, Michael C Brumm, et al.
Pageof 15

Showing results (71-80 of 144) with videos related to

Sort By:
Pageof 15
Journal of Parkinson'S Disease|August 28, 2019
Predicting Progression in Parkinson's Disease Using Baseline and 1-Year Change MeasuresLana M Chahine, Andrew Siderowf, Janel Barnes, et al.
Clinical and Translational Science|July 28, 2017
Dopamine Transporter Neuroimaging as an Enrichment Biomarker in Early Parkinson's Disease Clinical Trials: A Disease Progression Modeling AnalysisDaniela J Conrado, Timothy Nicholas, Kuenhi Tsai, et al.
The Lancet. Neurology|July 21, 2023
Safety and efficacy of venglustat in GBA1-associated Parkinson's disease: an international, multicentre, double-blind, randomised, placebo-controlled, phase 2 trialNir Giladi, Roy N Alcalay, Gary Cutter, et al.
Clinical and Translational Science|February 2, 2019
Molecular Neuroimaging of the Dopamine Transporter as a Patient Enrichment Biomarker for Clinical Trials for Early Parkinson's DiseaseKlaus Romero, Daniela Conrado, Jackson Burton, et al.
Annals of Neurology|April 27, 2026
Insights Gained From the PPMI Brain Donation ProgramTatiana Foroud, Laura E A Heathers, Syed Bukhari, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|August 20, 2009
A longitudinal program for biomarker development in Parkinson's disease: a feasibility studyBernard Ravina, Caroline Tanner, Diane Dieuliis, et al.
Annals of Neurology|May 6, 2026
Biologic Frameworks for Synucleinopathies: Contributions of the Parkinson's Progression Markers InitiativeLana M Chahine, Roy N Alcalay, Ethan G Brown, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|April 4, 2017
The prodromal phase of leucine-rich repeat kinase 2-associated Parkinson disease: Clinical and imaging StudiesClaustre Pont-Sunyer, Eduardo Tolosa, Chelsea Caspell-Garcia, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 13, 2019
Tau PET imaging with <sup>18</sup>F-PI-2620 in Patients with Alzheimer Disease and Healthy Controls: A First-in-Humans StudyAndre Mueller, Santiago Bullich, Olivier Barret, et al.
NPJ Parkinson'S Disease|October 22, 2022
Longitudinal clinical and biomarker characteristics of non-manifesting LRRK2 G2019S carriers in the PPMI cohortTanya Simuni, Kalpana Merchant, Michael C Brumm, et al.
Pageof 15